The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(15), P. 8805 - 8805

Published: Aug. 8, 2022

Modifications in the microbiota caused by environmental and genetic reasons can unbalance intestinal homeostasis, deregulating host's metabolism immune system, intensifying risk factors for development aggravation of non-alcoholic fat liver disease (NAFLD). The use probiotics, prebiotics synbiotics have been considered a potential promising strategy to regulate gut produce beneficial effects patients with conditions. For this reason, review aimed evaluate effectiveness prebiotics, symbiotics NAFLD NASH. Pubmed, Embase, Cochrane databases were consulted, PRISMA (Preferred Reporting Items Systematic Reviews Meta-Analysis) guidelines followed. clinical trials used study demonstrated that interventions could improve wide range markers inflammation, glycemia, insulin resistance, dyslipidemia, obesity, injury (decrease hepatic enzymes steatosis fibrosis). Although modulators do not play healing role, they work as an important adjunct therapy pathological processes involving its spectrums, either improving barrier or preventing formation toxic metabolites acting on system.

Language: Английский

---

Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis

Lipids in Health and Disease, Journal Year: 2023, Volume and Issue: 22(1)

Published: March 15, 2023

Abstract Background Lipid accumulation product (LAP) is an index calculated by waist circumference (WC) and triglyceride (TG), which reflects lipid toxicity. This study aims to investigate the association between LAP nonalcoholic fatty liver disease (NAFLD) in a systematic review meta-analysis. Methods results PubMed, Scopus, Web of Science online databases were searched for eligible studies that investigated NAFLD. Sixteen observational with 96,101 participants, including four cohort studies, one case‒control 11 cross-sectional baseline data, entered into this analysis. Fourteen reported significant NAFLD, two relation was not significant; different meta-analyses (1- mean difference (MD) 2- bivariate diagnostic test accuracy [DTA]) conducted using Stata version 14. The compared subjects without 34.90 units (CI 95: 30.59–39.31, P < 0.001) index. DTA meta-analysis showed pooled sensitivity specificity screening NAFLD 94% (CI95: 72%–99%, I 2 = 99%, 85% 62%–96%, 0.001), respectively. Conclusion Index inexpensive, sensitive, specific method evaluate may be valuable screening.

Language: Английский

---

The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease

Biomedicines, Journal Year: 2023, Volume and Issue: 11(2), P. 640 - 640

Published: Feb. 20, 2023

The prevalence of non-alcoholic fatty liver disease (NAFLD) has soared globally. As our understanding the grows, role gut-liver axis (GLA) in NAFLD pathophysiology becomes more apparent. Hence, we focused mainly on small intestinal area to explore GLA. We looked at how multi-strain probiotics (MCP® BCMC® strains) containing six different Lactobacillus and Bifidobacterium species affected gut microbiota, inflammatory cytokines, permeability patients. After months supplementation, biochemical blood analysis did not show any discernible alterations either group. Five predominant phyla known as Actinobacteria, Proteobacteria, Firmicutes, Bacteroidota Fusobacteria were found group demonstrated a significant cluster formation microbiota composition through beta-diversity (p < 0.05). This significantly reduced three unclassifiable species: unclassified_Proteobacteria, unclassified_Streptococcus, unclassified_Stenotrophomonas. In contrast, placebo showed increase Prevotella_melaninogenica Rothia_mucilaginosa, which classified pathogens. Real-time quantitative PCR mucosal cytokines revealed decrease IFN-γ (-7.9 ± 0.44, p 0.0001) TNF-α (-0.96 0.25, 0.0033) but an IL-6 (12.79 2.24, 0.0001). terms analysis, group, unfortunately, positive changes ELISA analysis. Both groups exhibited level circulating zonulin (probiotics: 107.6 ng/mL 124.7, = 0.005 vs. placebo: 106.9 101.3, 0.0002) zonula occluden-1 (ZO-1) -34.51 18.38, 0.0001 -33.34 16.62, consumption suggested presence well-balanced composition. Probiotic supplementation improves dysbiosis eventually stabilised expression immune function. To summarise, research probiotic supplement healthy diet lifestyle is required address its underlying causes.

Language: Английский

---

Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial

Journal of Nutrition, Journal Year: 2023, Volume and Issue: 153(7), P. 1984 - 1993

Published: May 22, 2023

Language: Английский

---

Effect of probiotic supplementation on gastrointestinal motility, inflammation, motor, non-motor symptoms and mental health in Parkinson’s disease: a meta-analysis of randomized controlled trials

Gut Pathogens, Journal Year: 2023, Volume and Issue: 15(1)

Published: March 6, 2023

Parkinson's disease (PD) is the second most common neurodegenerative worldwide. Gut dysbiosis hypothesized to cause PD; therefore, whether probiotics can be used as adjuvants in treatment of PD being actively investigated.We performed a systematic review and meta-analysis evaluate effectiveness probiotic therapy patients.PUBMED/MEDLINE, EMBASE, Cochrane, Scopus, PsycINFO Web Science databases were searched till February 20, 2023. The random effects model effect size was calculated mean difference or standardized difference. We assessed quality evidence using Grade Recommendations Assessment, Development Evaluation (GRADE) approach.Eleven studies involving 840 participants included final analysis. This showed high-quality improvement Unified Rating Scale Part III motor scale (standardized [95% confidence interval]) (- 0.65 [- 1.11 - 0.19]), non-motor symptom 0.81 1.12 0.51]), depression 0.70 0.93 -0.46]). Moderate low significant observed gastrointestinal motility (0.83 [0.45-1.10]), life 1.02 1.66 0.37]), anxiety 0.72 1.10 0.35]), serum inflammatory markers 5.98 9.20 2.75]), diabetes risk 3.46 4.72 2.20]). However, there no improvements Bristol Stool scores, constipation, antioxidant capacity, dyslipidemia. In subgroup analysis, capsules improved compared fermented milk.Probiotic supplements may suitable for improving symptoms reducing depression. Further research warranted determine mechanism action optimal protocol.

Language: Английский

---

Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Aug. 22, 2024

There is a contradiction in the use of microbiota-therapies, including probiotics, prebiotics, and synbiotics, to improve condition patients with nonalcoholic fatty liver disease (NAFLD). The aim this review was evaluate effect microbiota-therapy on injury, inflammation, lipid levels individuals NAFLD. Using Pubmed, Embase, Cochrane Library, Web Science databases were searched for articles prebiotic, probiotic, or synbiotic treatment NAFLD up March 2024. Thirty-four studies involving 12,682 included. Meta-analysis indicated that supplementation significantly improved injury (hepatic fibrosis, SMD = -0.31; 95% CI: -0.53, -0.09; aspartate aminotransferase, -0.35; -0.55, -0.15; alanine -0.48; -0.71, -0.25; alkaline phosphatase, -0.81; -1.55, -0.08), profiles (triglycerides, -0.22; -0.43, -0.02), inflammatory factors (high-density lipoprotein, -0.47; -0.88, -0.06; tumour necrosis factor alpha, -0.86 -1.56, -0.56). Overall, had positive reducing enzymes, profiles, cytokines

Language: Английский

---

Probiotic therapy, a novel and efficient adjuvant approach to improve glycemic status: An umbrella meta-analysis

Pharmacological Research, Journal Year: 2022, Volume and Issue: 183, P. 106397 - 106397

Published: Aug. 15, 2022

Language: Английский

---

The contribution of the gut-liver axis to the immune signaling pathway of NAFLD

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Aug. 31, 2022

Nonalcoholic fatty liver disease (NAFLD) is the manifestation of metabolic syndrome and most common chronic in world. The pathogenesis NAFLD has not been fully clarified; it involves disturbances, inflammation, oxidative stress, various forms cell death. "intestinal-liver axis" theory, developed recent years, holds that there a certain relationship between intestinal tract, changes flora are closely involved development NAFLD. Many studies have found regulates by affecting energy metabolism, inducing endotoxemia, producing endogenous ethanol, regulating bile acid choline metabolism. In this review, we highlighted updated discoveries dysregulation their link to mechanism summarized potential treatments related gut microbiome.

Language: Английский

---

Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Feb. 24, 2024

Increasing evidence indicates that gut microbiota are closely related to prostate cancer. This study aims assess the composition in patients with cancer compared healthy participants, thereby advancing understanding of microbiota's role

Language: Английский

---

Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial

Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11

Published: March 27, 2024

Background and aim Considering the increasing prevalence of non-alcoholic steatohepatitis (NASH) treatment gaps, this study aimed to evaluate effect probiotic supplementation on liver function markers, nutritional status, clinical parameters. Methods This double-blind, randomized trial ( ClinicalTrials.gov ID: NCT0346782) included adult outpatients with biopsy-proven NASH. The intervention consisted 24 weeks mix Lactobacillus acidophilus (1 × 10 9 CFU) + rhamnosus paracasei Bifidobacterium lactis CFU), or placebo, twice a day. following parameters were evaluated: demographic data, transient elastography (FibroScan), enzymes, NAFLD fibrosis score , fatty index, laboratory assessment, serum concentration toll-like receptor-4 (sTLR-4) cytokeratin 18 (CK-18), anthropometric dietary intake, physical activity. Regarding data analysis, comparison between groups was based delta difference each variable analyzed (value at end minus baseline value) using t -test for independent samples Mann–Whitney U -test. Results Forty-four patients NASH completed (51.4 ± 11.6 years). At baseline, 87% participants had mild degree biopsy, normal values consistent grade 1 in both groups, increased waist circumference (WC), BMI 30.97 kg/m 2 76% presented metabolic syndrome (MetS). After intervention, no differences observed placebo terms MetS, WC, scores, enzyme levels p &gt; 0.05 all). remained groups. Although CK-18 reduced larger size noted group D = 1.336). sTLR-4 also 0.885). Conclusion Intervention probiotics early stages demonstrated significant change hepatic Clinical registration identifier NCT0346782.

Language: Английский

---